SOMERSET, N.J., April 25, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced that business.com published a review of CareCloud's electronic health record (EHR) system Charts, providing an in-depth analysis of the platform's features, usability, and overall value for healthcare providers.
The business.com editor awarded CareCloud Charts an 8.9 out of 10, highlighing its user-friendly interface, which is designed to be intuitive and easy to navigate. The system's robust reporting and analytics capabilities enable providers to gain valuable insights into patient care and practice performance. The review also notes that Charts is highly customizable, offering a range of templates and workflows that can be tailored to the specific needs of individual practices and integrates seamlessly with third-party applications to allow for streamlined data exchange and improved interoperability.
"As the healthcare industry has shifted towards electronic health records, most everyone has a system in place, but not all are using them to their fullest capabilities," said Iram Fatima, M.B.B.S., CareCloud’s chief operating officer for electronic health records and digital health. "That's where CareCloud's EHR solution comes in. We created an EHR system that simplifies the process and helps medical practices take full advantage of the benefits of an EHR. Our goal is to empower providers with the tools they need to deliver better patient care and improve practice performance."
Charts is just one of the many healthcare technology solutions offered by the company. CareCloud is committed to providing healthcare providers with technology-enabled solutions that enhance every aspect of a medical practice, including technology-enabled revenue cycle management (RCM). The tools within CareCloud’s comprehensive suite of solutions are designed to streamline billing processes, increase collections, and improve financial performance. Through its EHR system and other healthcare technology solutions, CareCloud aims to empower medical practices with the tools they need to deliver high-quality patient care while achieving greater efficiency and profitability.
To learn more about CareCloud’s comprehensive suite of technology-enabled services and solutions, visit carecloud.com/solutions.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Company Contact:
Bill Korn
Chief Financial Officer
CareCloud
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.25 |
Daily Change: | -0.01 -0.79 |
Daily Volume: | 645,400 |
Market Cap: | US$20.320M |
April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 January 28, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load